Product Code: GDHC487DFR
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Squalamine (Squalamine lactate) is a first-in-class drug being developed by Ohr Pharmaceuticals as a novel eye drop solution treatment for wAMD. This small-molecule drug has a novel intracellular mechanism of action and can potently inhibit multiple protein growth factors involved in angiogenesis, including VEGF, PDGF, and bFGF.
Scope
- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Squalamine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Squalamine for the top country from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain and UK
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Squalamine performance.
- Obtain sales forecast for Squalamine from 2013-2023 in top 6 countries (the US, France, Germany, Italy, Spain and UK).
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
2. Introduction
3. Disease Overview
- 3.1. Macular Degeneration Overview
- 3.1.1. Etiology and Pathophysiology
- 3.1.2. Classification
- 3.1.3. Symptoms and Diagnosis
- 3.2. Macular Edema Overview
- 3.2.1. Etiology and Pathophysiology
- 3.2.2. Classification
- 3.2.3. Symptoms and Diagnosis
4. Disease Management
- 4.1. Diagnosis and Treatment Overview
- 4.1.1. Macular Edema Diagnosis
- 4.1.2. Macular Degeneration Diagnosis
- 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
- 4.1.4. Clinical Practice
5. Competitive Assessment
6. Unmet Need and Opportunity
- 6.1. Overview
- 6.2. Treatment for Dry AMD
- 6.2.1. Unmet Need
- 6.2.2. Gap Analysis
- 6.2.3. Opportunity
- 6.3. Longer-Acting Anti-VEGF Drug Therapy
- 6.3.1. Unmet Need
- 6.3.2. Gap Analysis
- 6.3.3. Opportunity
- 6.4. Increased Efficacy of Anti-VEGF Therapy for wAMD
- 6.4.1. Unmet Need
- 6.4.2. Gap Analysis
- 6.4.3. Opportunity
- 6.5. Less Invasive Drug Formulations
- 6.5.1. Unmet Need
- 6.5.2. Gap Analysis
- 6.5.3. Opportunity
- 6.6. Awareness and Earlier Patient Diagnosis
- 6.6.1. Unmet Need
- 6.6.2. Gap Analysis
- 6.6.3. Opportunity
- 6.7. Home Monitoring of AMD Progression
- 6.7.1. Unmet Need
- 6.7.2. Gap Analysis
- 6.7.3. Opportunity
7. Pipeline Assessment
- 7.1. Overview
- 7.2. Promising Drugs in Clinical Development
8. Squalamine
- 8.1. Overview
- 8.2. Efficacy
- 8.3. Safety
- 8.4. Dosing and Formulation
- 8.5. Potential Clinical and Commercial Positioning
8.6. SWOT Analysis
9. Appendix
- 9.1. Bibliography
- 9.2. Abbreviations
- 9.3. Methodology
- 9.4. Forecasting Methodology
- 9.4.1. Diagnosed ME and AMD Patients
- 9.4.2. Percentage of Drug-Treated Patients
- 9.4.3. General Pricing Assumptions
- 9.4.4. Pricing of Pipeline Agents
- 9.5. Primary Research - KOLs Interviewed for this Report
- 9.6. Primary Research - High-Prescribers Survey
- 9.7. About the Authors
- 9.7.1. Analyst
- 9.7.2. Therapy Area Director
- 9.7.3. Global Head of Healthcare
- 9.8. About GlobalData
- 9.9. Disclaimer
List of Tables
- Table 1: ARM System Classification of AMD
- Table 2: Symptoms of AMD
- Table 3: National and International Treatment Guidelines for ME and AMD
- Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
- Table 5: Leading Treatments for ME and AMD, 2014
- Table 6: Unmet Needs and Opportunities in ME and AMD
- Table 7: Promising Drugs in Clinical Development for ME and AMD
- Table 8: Comparison of Drugs in Development for ME and AMD, 2014
- Table 9: Product Profile - Squalamine
- Table 10: SWOT Analysis - Squalamine, 2014
- Table 11: Global Sales Forecast ($m) for Squalamine, 2013-2023
- Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country
List of Figures
- Figure 1: Anatomy of the Eye and Macula
- Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
- Figure 3: Color Fundus Photographs of Dry and Wet AMD
- Figure 4: FAF Imaging of GA
- Figure 5: Imaging of wAMD
- Figure 6: CMT in DME
- Figure 7: RVOs (BRVO and CRVO) on an FA
- Figure 8: Increased CRT in ME-RVO
- Figure 9: ME Clinical Treatment Flowchart
- Figure 10: AMD Clinical Treatment Flowchart
- Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
- Figure 12: Squalamine's Clinical Development in wAMD and DME
- Figure 13: Clinical and Commercial Positioning of Squalamine
